Edaravone
Orphan DrugFDA Approved
Description
Edaravone is a free radical scavenger used to slow the decline in function in amyotrophic lateral sclerosis (ALS). It is administered intravenously.
Indications & Therapeutic Use
Amyotrophic Lateral Sclerosis (ALS)
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Edaravone
| Generic Name | Edaravone |
| Brands | 1 brand available |
| Active Ingredient | Edaravone |
| Drug Class | Amyotrophic Lateral Sclerosis (ALS) |
| Manufacturer | Mitsubishi Tanabe Pharma |
| Dosage Forms | IV infusion |
| Medical Code | M01AX22 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02231353 |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes